FIMECS develops protein degradation therapeutics using its proprietary RaPPIDS™ technology to target previously undruggable proteins associated with cancers and difficult-to-treat diseases. The company aims to provide life-saving medicines by addressing unmet medical needs through collaborations with various research institutions and industry partners.
Funding
$26.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-causing proteins are considered "undruggable" because they lack traditional binding sites for small-molecule inhibitors, hindering the development of effective therapies. This limitation leaves a significant number of diseases, including various cancers, without targeted treatment options.
Solution
FIMECS is a drug discovery company focused on developing novel protein degradation therapeutics. Their proprietary RaPPIDS™ technology platform enables the targeting and degradation of previously undruggable proteins. By selectively removing these proteins, FIMECS aims to create first-in-class drugs for cancers and other diseases with high unmet medical needs. The RaPPIDS™ platform utilizes E3 ligase binding molecules to induce the degradation of target proteins.
Target Audience
The primary target audience includes patients suffering from cancers and other diseases lacking effective treatment options, as well as pharmaceutical companies and research institutions seeking innovative drug discovery platforms.
Features
- RaPPIDS™ technology platform for targeted protein degradation
- Focus on E3 ligase recruitment for protein knockdown
- Development of first-in-class drugs against previously undruggable targets
- Applications in oncology and other therapeutic areas
- Collaborative research programs with pharmaceutical companies and academic institutions